2 files

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

posted on 30.10.2019, 12:46 by Michael J. Palte, Angela Wehr, Mark Tawa, Kristopher Perkin, Richard Leigh-Pemberton, Jerome Hanna, Catherine Miller, Natasha Penner

The above Summary Slide and Video represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2021.